from Reuters: Health News http://ift.tt/2ontnOY
Sangamo in $3 billion gene-editing deal with Gilead
(Reuters) - U.S. drugmaker Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion to Sangamo, the companies said on Thursday.
from Reuters: Health News http://ift.tt/2ontnOY
from Reuters: Health News http://ift.tt/2ontnOY
Subscribe to:
Post Comments (Atom)
-
The German cabinet will hold a secret session on Wednesday to discuss safeguard measures regarding the possible participation of China's...
-
Stocks poised for another day of gains Equity markets look to add to the gains from the prior session as investor concerns about the fu...
-
By LIAM STACK from NYT Magazine https://ift.tt/2FNPp6k
No comments:
Post a Comment